Title:Titanocenes as Anticancer Agents: Recent Insights
Volume: 13
Issue: 4
Author(s): Hana Skoupilova, Roman Hrstka*Martin Bartosik*
Affiliation:
- Masaryk Memorial Cancer Institute, RECAMO, Zluty kopec 7, 656 53, Brno,Czech Republic
- RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno,Czech Republic
Keywords:
Chemotherapy, cisplatin, clinical trials, organometallic compounds, titanocene compounds, titanocene dichloride.
Abstract: Background: Enormous success of antitumor agent cisplatin initiated interest in other
organometallic complexes. A subclass of organometallic compounds termed metallocenes,
characterized by a transition metal central atom (M) bound to cyclopentadienide (Cp-/[C5H5]-)
ligands with the basic formula Cp2M, has gained increasing interest as promising anticancer
agents.
Objectives: This review summarizes the progress in the development of organometallic titaniumbased
compounds focusing primarily on the evaluation of their cytotoxic activity and mechanism
of action in relation to potential utilization as anticancer drugs.
Results: Metallocenes bearing titanium as central atom were sorted according to their structure
and modifications and their anticancer activity is further discussed.
Conclusion: Titanocenes represent family of promising compounds exerting cytostatic activity.
We suggest that their application not only as separate agents, but also in combination with newly
developed carriers, e.g. nanomaterials, may lead to improvement of their delivery into tumor cells
and following utilization in cancer treatment.
